^
Association details:
| Biomarker: | ALK wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + Kaitanni (cadonilimab) (PD1 inhibitor, CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer
Published date:
12/18/2023
Excerpt:
This study aimed to assess the safety and efficacy of cadonilimab plus anlotinib for the first-line treatment of advanced non-small cell lung cancer (NSCLC) without sensitizing EGFR/ALK/ROS1 mutations….Cadonilimab 10 mg/kg Q3W plus anlotinib showed manageable safety and promising efficacy as a first-line chemo-free treatment for advanced NSCLC.
DOI:
https://doi.org/10.1038/s41416-023-02519-0
Trial ID:
